2'-O-Methylpseudo-UTP A Modified Nucleotide for Enhanced mRN

2'-O-Methylpseudo-UTP: A Modified Nucleotide for Enhanced mRNA Therapeutics and Research Applications
Introduction [Related: Concanavalin A (Con A)-HyperFluor™ 647]
2'-O-Methylpseudo-UTP (2'-O-MeΨ-UTP) is a chemically modified nucleotide analog of uridine triphosphate (UTP), characterized by the addition of a methyl group at the 2'-O position and the isomerization of uridine to pseudouridine. This dual modification imparts unique physicochemical and biological properties, making 2'-O-MeΨ-UTP a valuable tool in the synthesis of modified messenger RNA (mRNA) for therapeutic and research applications (Karikó et al., 2008, Molecular Therapy). The incorporation of 2'-O-MeΨ-UTP into mRNA has been shown to enhance transcript stability, reduce innate immune activation, and improve translational efficiency, thereby addressing several key challenges in the development of mRNA-based therapeutics and vaccines (Andries et al., 2015, Nucleic Acids Research). [Related: cocktail protease inhibitor]
Mechanistically, 2'-O-MeΨ-UTP is recognized and incorporated by RNA polymerases during in vitro transcription (IVT) reactions, replacing canonical uridine residues. The 2'-O-methyl modification confers resistance to nuclease degradation, while the pseudouridine base reduces recognition by pattern recognition receptors such as Toll-like receptors (TLRs) and retinoic acid-inducible gene I (RIG-I)-like receptors (Karikó et al., 2005, Immunity). These properties collectively enhance the pharmacological profile of mRNA molecules, making 2'-O-MeΨ-UTP an essential component in the next generation of nucleic acid-based therapeutics. [Related: protease inhibitor cocktail tablets]
Clinical Value and Applications
The clinical value of 2'-O-MeΨ-UTP is most prominently realized in the field of mRNA therapeutics, including vaccines, protein replacement therapies, and gene editing platforms. The COVID-19 pandemic highlighted the transformative potential of mRNA vaccines, many of which utilize modified nucleotides such as 2'-O-MeΨ-UTP to optimize their efficacy and safety profiles (Sahin et al., 2020, Nature Reviews Drug Discovery).
1. **mRNA Vaccines:** The use of 2'-O-MeΨ-UTP in mRNA vaccines enhances antigen expression and reduces immunogenicity, resulting in improved vaccine potency and tolerability. This modification is a cornerstone in the design of clinically approved mRNA vaccines against SARS-CoV-2 (Polack et al., 2020, New England Journal of Medicine).
2. **Protein Replacement Therapies:** For genetic disorders caused by protein deficiencies, mRNA encoding the therapeutic protein can be synthesized with 2'-O-MeΨ-UTP to increase stability and translation, allowing for effective protein replacement with reduced dosing frequency (Sahin et al., 2014, Molecular Therapy).
3. **Gene Editing and Cell Therapy:** Modified mRNAs incorporating 2'-O-MeΨ-UTP are used to transiently express gene editing tools (e.g., CRISPR-Cas9) or reprogramming factors in cell therapy applications, minimizing the risk of genomic integration and immune activation (Warren et al., 2010, Cell Stem Cell).
4. **Basic Research:** In vitro and in vivo studies of RNA biology benefit from the use of 2'-O-MeΨ-UTP-modified transcripts, which are more stable and less likely to induce confounding immune responses, facilitating accurate mechanistic studies (Andries et al., 2015).
Key Challenges and Pain Points Addressed
The development and deployment of mRNA-based therapeutics face several challenges that 2'-O-MeΨ-UTP helps to address:
- **Innate Immune Activation:** Unmodified mRNA is recognized by innate immune sensors, triggering inflammatory responses that can reduce therapeutic efficacy and cause adverse effects. 2'-O-MeΨ-UTP-modified mRNA evades detection by TLRs and RIG-I, significantly reducing immunogenicity (Karikó et al., 2005).
- **mRNA Stability:** Natural mRNA is susceptible to rapid degradation by nucleases, limiting its half-life and therapeutic window. The 2'-O-methyl modification increases resistance to exonucleases and endonucleases, prolonging mRNA stability in biological environments (Andries et al., 2015).
- **Translational Efficiency:** Modified nucleotides can enhance ribosome recruitment and translation, leading to higher protein yields from the same amount of mRNA (Sahin et al., 2014).
- **Manufacturing Consistency:** The use of 2'-O-MeΨ-UTP in IVT reactions is compatible with large-scale, GMP-compliant mRNA manufacturing, supporting the translation of research findings into clinical products (Sahin et al., 2020).
Literature Review
A growing body of literature supports the utility of 2'-O-MeΨ-UTP in mRNA therapeutics and research:
1. **Karikó et al. (2005, Immunity):** Demonstrated that incorporation of pseudouridine and 2'-O-methyl modifications into mRNA reduces activation of TLRs and RIG-I, resulting in diminished innate immune responses in vitro and in vivo.
2. **Karikó et al. (2008, Molecular Therapy):** Showed that mRNA containing 2'-O-methyl and pseudouridine modifications is more stable and produces higher levels of protein expression in mammalian cells compared to unmodified mRNA.
3. **Andries et al. (2015, Nucleic Acids Research):** Systematically evaluated the effects of various modified nucleotides, including 2'-O-MeΨ-UTP, on mRNA stability and translation, confirming superior performance in terms of reduced immunogenicity and enhanced protein production.
4. **Warren et al. (2010, Cell Stem Cell):** Used synthetic mRNAs with 2'-O-methyl and pseudouridine modifications to reprogram human somatic cells into pluripotent stem cells, demonstrating efficient protein expression with minimal immune activation.
5. **Sahin et al. (2014, Molecular Therapy):** Reviewed the impact of nucleotide modifications on mRNA therapeutics, highlighting the clinical relevance of 2'-O-MeΨ-UTP in improving the safety and efficacy of mRNA-based drugs.
6. **Polack et al. (2020, New England Journal of Medicine):** Reported on the clinical efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine, which incorporates modified nucleotides, including 2'-O-methylpseudouridine, to optimize immunogenicity and tolerability.
7. **Sahin et al. (2020, Nature Reviews Drug Discovery):** Provided an overview of mRNA vaccine technology, emphasizing the role of modified nucleotides such as 2'-O-MeΨ-UTP in overcoming key developmental barriers.
Experimental Data and Results
Experimental evidence consistently demonstrates the advantages of 2'-O-MeΨ-UTP in mRNA synthesis and function:
- **Reduced Immunogenicity:** Karikó et al. (2005) found that mRNAs containing 2'-O-MeΨ-UTP elicited significantly lower levels of interferon-α and pro-inflammatory cytokines in human peripheral blood mononuclear cells compared to unmodified mRNA.
- **Enhanced Protein Expression:** In vitro translation assays and cell-based experiments have shown that mRNAs synthesized with 2'-O-MeΨ-UTP produce 2- to 10-fold higher protein yields than their unmodified counterparts (Karikó et al., 2008; Andries et al., 2015).
- **Improved Stability:** Modified mRNAs exhibit prolonged half-lives in serum and cellular environments, with 2'-O-MeΨ-UTP conferring resistance to RNase-mediated degradation (Andries et al., 2015).
- **Clinical Translation:** The success of mRNA vaccines against COVID-19, as reported by Polack et al. (2020), provides real-world validation of the clinical utility of 2'-O-MeΨ-UTP-modified mRNA, with high efficacy and favorable safety profiles observed in large-scale clinical trials.
- **Cellular Reprogramming:** Warren et al. (2010) demonstrated that 2'-O-MeΨ-UTP-modified mRNAs could efficiently reprogram human fibroblasts to pluripotency, with negligible activation of innate immune pathways.
Usage Guidelines and Best Practices
For optimal results, the following guidelines are recommended when using 2'-O-MeΨ-UTP in mRNA synthesis:
- **Incorporation Ratio:** Substitute 100% of canonical UTP with 2'-O-MeΨ-UTP during IVT reactions for maximal immunogenicity reduction and stability. Partial substitution can be considered for specific applications requiring fine-tuned immune responses (Karikó et al., 2008).
- **Enzyme Selection:** Use high-fidelity T7, SP6, or T3 RNA polymerases compatible with modified nucleotides. Enzyme selection may affect incorporation efficiency and transcript yield.
- **Capping and Polyadenylation:** Employ co-transcriptional capping (e.g., CleanCap) and enzymatic polyadenylation to further enhance mRNA stability and translational efficiency.
- **Purification:** Purify synthesized mRNA using high-performance liquid chromatography (HPLC) or fast protein liquid chromatography (FPLC) to remove double-stranded RNA contaminants and residual reactants, which can contribute to immunogenicity.
- **Storage and Handling:** Store 2'-O-MeΨ-UTP and synthesized mRNA at -80°C in RNase-free conditions. Avoid repeated freeze-thaw cycles to maintain nucleotide integrity.
- **Quality Control:** Assess mRNA integrity by agarose gel electrophoresis and quantify purity using UV spectrophotometry or fluorometric assays. Confirm incorporation of 2'-O-MeΨ-UTP by mass spectrometry or enzymatic digestion followed by HPLC.
- **In Vivo Delivery:** Formulate mRNA with lipid nanoparticles (LNPs) or other delivery vehicles to protect against degradation and facilitate cellular uptake.
Future Research Directions
Despite significant progress, further research is warranted to expand the utility and understanding of 2'-O-MeΨ-UTP:
- **Structure-Function Relationships:** Systematic studies on the impact of varying degrees and patterns of 2'-O-methyl and pseudouridine modifications on mRNA structure, translation, and immunogenicity.
- **Combination with Other Modifications:** Exploration of synergistic effects between 2'-O-MeΨ-UTP and other modified nucleotides (e.g., N1-methylpseudouridine, 5-methylcytidine) to further optimize mRNA properties.
- **Long-Term Safety:** Longitudinal studies assessing the safety and immunogenicity of repeated administration of 2'-O-MeΨ-UTP-modified mRNA in diverse patient populations.
- **Expanded Therapeutic Indications:** Application of 2'-O-MeΨ-UTP-modified mRNA in emerging areas such as personalized cancer vaccines, regenerative medicine, and rare genetic diseases.
- **Manufacturing Innovations:** Development of scalable, cost-effective synthesis and purification methods for 2'-O-MeΨ-UTP and modified mRNA to support global access to mRNA therapeutics.
Conclusion
2'-O-Methylpseudo-UTP represents a critical advancement in the field of mRNA therapeutics and molecular biology research. Its unique chemical modifications confer enhanced stability, reduced immunogenicity, and improved translational efficiency, addressing key challenges in the development of nucleic acid-based medicines. Supported by robust experimental and clinical evidence, 2'-O-MeΨ-UTP is poised to play a central role in the next generation of vaccines, protein replacement therapies, and gene editing technologies. Ongoing research and innovation will further unlock its potential, driving progress in precision medicine and beyond.
References
- Karikó K, Buckstein M, Ni H, Weissman D. (2005). Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity, 23(2), 165-175. - Karikó K, Muramatsu H, Ludwig J, Weissman D. (2008). Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Molecular Therapy, 16(11), 1833-1840. - Andries O, Mc Cafferty S, De Smedt SC, Weiss R, Sanders NN, Kitada T. (2015). N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. Nucleic Acids Research, 43(21), 10168-10178. - Warren L, Manos PD, Ahfeldt T, et al. (2010). Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell, 7(5), 618-630. - Sahin U, Karikó K, Türeci Ö. (2014). mRNA-based therapeutics—developing a new class of drugs. Molecular Therapy, 22(5), 759-771. - Polack FP, Thomas SJ, Kitchin N, et al. (2020). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine, 383(27), 2603-2615. - Sahin U, Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 7169 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11581937